Du benytter en nettleser vi ikke støtter. Se informasjon om nettlesere

13. Referanser

  1. Louis DN, Ohgaki H, Wiestler OW, Cavenee WK, red. WHO classification of tumours of the central nervous system. 4. rev. utg. Lyon: IARC Press; 2016. Tumours of the Central nervous system
  2. Lloyd RV, Osamura RY, Klöppel G, Rosai J, red. WHO classification of tumours of endocrine organs. 4. utg. Lyon: International agency for research on cancer; 2017.
  3. Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathol 2018;136(5):805-10.
  4. Cancer in Norway 2012 - cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2014.
  5. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol 2017;19(suppl_5):v1-v88.
  6. Michaud D, Batchelor T. Risk factors for brain tumors. UpToDate [database]. Waltham, MA.: UpToDate, Inc [oppdatert 2017; lest 2. oktober 2017].
  7. Lov om pasient- og brukerrettigheter (pasient- og brukerrettighetsloven). LOV-1999-07-02-63. Sist endret i: LOV-2019-12-20-104 fra 01.03.2020. Tilgjengelig fra: https://lovdata.no/dokument/NL/lov/1999-07-02-63 
  8. Forskrift om prioritering av helsetjenester, rett til nødvendig helsehjelp fra spesialisthelsetjenesten, rett til behandling i utlandet og om klagenemnd (prioriteringsforskriften). FOR-2000-12-01-1208. Sist endret i: FOR-2020-02-04-119 fra 01.03.2020. Tilgjengelig fra: https://lovdata.no/dokument/SF/forskrift/2000-12-01-1208 
  9. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol 2004;3(3):159-68.
  10.  Englot DJ, Chang EF, Vecht CJ. Epilepsy and brain tumors. Handb Clin Neurol 2016;134:267-85.
  11. Armstrong TS, Grant R, Gilbert MR, Lee JW, Norden AD. Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy. Neuro Oncol 2016;18(6):779-89.
  12. Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas. Epilepsia 2013;54 Suppl 9:12-7.
  13. Nelson S, Taylor LP. Headaches in brain tumor patients: primary or secondary? Headache 2014;54(4):776-85.
  14. Bitar R, Leung G, Perng R, Tadros S, Moody AR, Sarrazin J, et al. MR pulse sequences: what every radiologist wants to know but is afraid to ask. Radiographics 2006;26(2):513-37.
  15. Mabray MC, Barajas RF, Jr., Cha S. Modern brain tumor imaging. Brain tumor research and treatment 2015;3(1):8-23.
  16. Mikulis DJ, Roberts TP. Neuro MR: protocols. J Magn Reson Imaging 2007;26(4):838-47.
  17. Roberts TP, Mikulis D. Neuro MR: principles. J Magn Reson Imaging 2007;26(4):823-37.
  18. Castillo M. History and evolution of brain tumor imaging: insights through radiology. Radiology 2014;273(2 Suppl):S111-25.
  19. Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol 2015;17(9):1188-98.
  20. Svolos P, Kousi E, Kapsalaki E, Theodorou K, Fezoulidis I, Kappas C, et al. The role of diffusion and perfusion weighted imaging in the differential diagnosis of cerebral tumors: a review and future perspectives. Cancer Imaging 2014;14:20.
  21. Majos C, Aguilera C, Alonso J, Julia-Sape M, Castaner S, Sanchez JJ, et al. Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses. AJNR Am J Neuroradiol 2009;30(3):544-51.
  22. Galldiks N, Langen KJ, Pope WB. From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol 2015;17(11):1434-44.
  23. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28(11):1963-72.
  24. Quant EC, Wen PY. Response assessment in neuro-oncology. Curr Oncol Rep 2011;13(1):50-6.
  25. Caroline I, Rosenthal MA. Imaging modalities in high-grade gliomas: pseudoprogression, recurrence, or necrosis? J Clin Neurosci 2012;19(5):633-7.
  26. Tran DK, Jensen RL. Treatment-related brain tumor imaging changes: So-called "pseudoprogression" vs. tumor progression: Review and future research opportunities. Surg Neurol Int 2013;4(Suppl 3):S129-35.
  27. Huang RY, Neagu MR, Reardon DA, Wen PY. Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol 2015;6:33.
  28. Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol 2017;19(5):625-35.
  29. Hemminki K, Tretli S, Olsen JH, Tryggvadottir L, Pukkala E, Sundquist J, et al. Familial risks in nervous system tumours: joint Nordic study. Br J Cancer 2010;102(12):1786-90.
  30. Hemminki K, Tretli S, Sundquist J, Johannesen TB, Granstrom C. Familial risks in nervous-system tumours: a histology-specific analysis from Sweden and Norway. Lancet Oncol 2009;10(5):481-8.
  31. Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med 2015;373(24):2336-46.
  32. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 2015;122(1):4-23.
  33. Shaw E, Arusell R, Scheithauer B, O'Fallon J, O'Neill B, Dinapoli R, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20(9):2267-76.
  34. Landberg T, Chavaudra J, Dobbs J, Gerard JP, Hanks G, Horiot JC, et al. Report 62: prescribing, recording and reporting photon beam therapy (Supplement to ICRU report 50). Journal of the ICRU 1999;os32(1).
  35. Indelicato DJ, Merchant T, Laperriere N, Lassen Y, Vennarini S, Wolden S, et al. Consensus Report From the Stockholm Pediatric Proton Therapy Conference. Int J Radiat Oncol Biol Phys 2016;96(2):387-92.
  36. Dale E, Waldeland E. Protonterapi - en realitet i Norge fra 2023. Tidsskr Nor Legeforen 2018;138(13).
  37. Boele FW, Klein M, Reijneveld JC, Verdonck-de Leeuw IM, Heimans JJ. Symptom management and quality of life in glioma patients. CNS oncology 2014;3(1):37-47.
  38. Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. Neuro Oncol 2015;17(4):488-504.
  39. Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol 2010;23(6):597-602.
  40. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55(4):475-82.
  41. Khan RB, Onar A. Seizure recurrence and risk factors after antiepilepsy drug withdrawal in children with brain tumors. Epilepsia 2006;47(2):375-9.
  42. Perucca E. Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia 2013;54 Suppl 9:97-104.
  43. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007;6(5):421-30.
  44. Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 2008;(2):CD004424.
  45. Koubeissi M. Do we need seizure prophylaxis for brain tumor surgery? Epilepsy Curr 2014;14(1):24-5.
  46. Kerrigan S, Grant R. Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst Rev 2011;(8):CD008586.
  47. Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frenay M, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 2010;17(9):1124-33.
  48. Cote DJ, Smith TR. Venous thromboembolism in brain tumor patients. J Clin Neurosci 2016;25:13-8.
  49. Perry JR. Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents. Curr Opin Neurol 2010;23(6):592-6.
  50. Silvani A, Gaviani P, Lamperti E, Botturi A, Ferrari D, Simonetti G, et al. Metabolic, electrolytes disorders and tromboembolic risk in malignant glioma patients. Neurol Sci 2011;32 Suppl 2:S229-31.
  51. Taillibert S, Taillandier L, Le Rhun E. Venous thrombosis in patients with high-grade glioma. Curr Opin Oncol 2015;27(6):516-21.
  52. Lee EQ, Wen PY. Treatment and prevention of venous thromboembolism in patients with brain tumors. UpToDate [database]. Waltham, MA: UpToDate, Inc [oppdatert 24. april 2020; lest 8. juni 2020]. Tilgjengelig fra: https://www.uptodate.com/contents/treatment-and-prevention-of-venous-thromboembolism-in-patients-with-brain-tumors 
  53. Stupp R, Tonn JC, Brada M, Pentheroudakis G. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v190-3.
  54. Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM, Neelis KJ, Biermasz NR, Romijn JA, et al. Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96(8):2330-40.
  55. Finch E, Copland DA. Language outcomes following neurosurgery for brain tumours: a systematic review. NeuroRehabilitation 2014;34(3):499-514.
  56. Gehring K, Sitskoorn MM, Aaronson NK, Taphoorn MJ. Interventions for cognitive deficits in adults with brain tumours. Lancet Neurol 2008;7(6):548-60.
  57. Gehring K, Sitskoorn MM, Gundy CM, Sikkes SA, Klein M, Postma TJ, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol 2009;27(22):3712-22.
  58. Huang ME, Cifu DX, Keyser-Marcus L. Functional outcome after brain tumor and acute stroke: a comparative analysis. Arch Phys Med Rehabil 1998;79(11):1386-90.
  59. O'Dell MW, Barr K, Spanier D, Warnick RE. Functional outcome of inpatient rehabilitation in persons with brain tumors. Arch Phys Med Rehabil 1998;79(12):1530-4.
  60. Waagemans ML, van Nieuwenhuizen D, Dijkstra M, Wumkes M, Dirven CM, Leenstra S, et al. Long-term impact of cognitive deficits and epilepsy on quality of life in patients with low-grade meningiomas. Neurosurgery 2011;69(1):72-8; discussion 8-9.
  61. Zucchella C, Capone A, Codella V, De Nunzio AM, Vecchione C, Sandrini G, et al. Cognitive rehabilitation for early post-surgery inpatients affected by primary brain tumor: a randomized, controlled trial. J Neurooncol 2013;114(1):93-100.
  62. Khan F, Amatya B, Ng L, Drummond K, Galea M. Multidisciplinary rehabilitation after primary brain tumour treatment. Cochrane Database Syst Rev 2015;(8):CD009509.
  63. Liu R, Page M, Solheim K, Fox S, Chang SM. Quality of life in adults with brain tumors: current knowledge and future directions. Neuro Oncol 2009;11(3):330-9.
  64. Lov om helsepersonell m.v. (helsepersonelloven). LOV-1999-07-02-64. Sist endret i: LOV-2019-04-10-11 fra 01.10.2019.
  65. Ichimura K, Narita Y, Hawkins CE. Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. Acta Neuropathol 2015;129(6):789-808.
  66. Korshunov A, Casalini B, Chavez L, Hielscher T, Sill M, Ryzhova M, et al. Integrated molecular characterization of IDH-mutant glioblastomas. Neuropathol Appl Neurobiol 2019;45(2):108-18.
  67. Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 2015;130(6):815-27.
  68. Berghoff AS, Stefanits H, Woehrer A, Heinzl H, Preusser M, Hainfellner JA. Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. Clin Neuropathol 2013;32(3):148-58.
  69. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24(18):2707-14.
  70. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31(3):337-43.
  71. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31(3):344-50.
  72. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24(18):2715-22.
  73. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27(25):4150-4.
  74. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360(8):765-73.
  75. Bello MJ, Alonso ME, Aminoso C, Anselmo NP, Arjona D, Gonzalez-Gomez P, et al. Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutat Res 2004;554(1-2):23-32.
  76. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003.
  77. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96.
  78. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012;13(9):916-26.
  79. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-15.
  80. Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013;81(17):1515-22.
  81. Preusser M, Berghoff AS, Manzl C, Filipits M, Weinhausel A, Pulverer W, et al. Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. Clin Neuropathol 2014;33(1):6-14.
  82. Pekmezci M, Perry A. Neuropathology of brain metastases. Surg Neurol Int 2013;4(Suppl 4):S245-55.
  83. Nasjonal helseplan (2007–2010). Oslo: Helse- og omsorgsdepartementet; 2006. Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6. Tilgjengelig fra: https://www.regjeringen.no/globalassets/upload/hod/sykehus/nasjonal_helseplan_sartrykk.pdf 
  84. Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven). LOV-2011-06-24-30. Sist endret i: LOV-2019-06-21-45 fra 01.01.2020. Tilgjengelig fra: https://lovdata.no/dokument/NL/lov/2011-06-24-30 
  85. Nasjonal strategi for kreftområdet 2006-2009. Oslo: Helse- og omsorgsdepartementet; 2006. Tilgjengelig fra: https://www.regjeringen.no/no/dokumenter/nasjonal-strategi-for-kreftomradet/id446845/ 
  86. Sammen - mot kreft: nasjonal kreftstrategi 2013-2017. Oslo: Helse- og omsorgsdepartementet; 2013. Tilgjengelig fra: https://www.regjeringen.no/no/dokumenter/sammen---mot-kreft/id728818/ 
  87. Leve med kreft: nasjonal kreftstrategi (2018–2022). Oslo: Helse- og omsorgsdepartementet; 2018. Tilgjengelig fra: https://www.regjeringen.no/no/dokumenter/leve-med-kreft/id2598282/

Sist faglig oppdatert: 31. desember 2020